APS 2012: Acute Pain

Recent research has resulted in a very rich pipeline of new agents to treat migraine, said David Dodick, MD, in presenting the Global Year Against Pain Lecture at the American Pain Society’s 31st Annual Scientific Meeting.

Using nano-formulated, lower-dose NSAIDs may provide clinical benefit for relieving mild to moderate acute pain, reported Garen Manvelian, MD, with Iroko Pharmaceuticals, Philadelphia, PA, at the American Pain Society’s 31st Annual Scientific Meeting.

Flurbiprofen 8.75mg lozenge provides lasting relief of pharyngeal pain, noted Dr. Bernard Schachtel, from New York University, New York, NY, at the American Pain Society’s 31st Annual Scientific Meeting.

Panadol Advance (paracetamol; fast-absorbing) 1,000mg tablets were more efficacious and demonstrated faster onset and longer duration of pain relief compared with Panadol Advance 500mg, standard paracetamol 650mg, and placebo, reported Yong Yue, MD, from Jean Brown Research, Salt Lake City, UT at the American Pain Society’s 31st Annual Scientific Meeting.

At the American Pain Society’s 31st Annual Scientific Meeting, Jon Levine, MD, PhD discussed recent data showing that kappa-opioids, generally observed to be less effective in providing pain relief than mu-receptor opioids, were not only equally effective in producing pain relief in a female patient population, but were also associated with a reduced incidence of adverse effects and greater overall patient satisfaction.

Intravenous (IV) prochlorperazine is more effective for the acute treatment of refractory migraine in pediatric patients than IV metoclopramide or valproate sodium. Shannon Cherney, MSN, CNP, from the Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, and colleagues sought to evaluate the efficacy of various IV pharmacotherapy options for primary intractable headache in children. The results were presented today at the American Pain Society’s 31st Annual Scientific Meeting.

Acetaminophen 1,000mg does provide an incremental benefit vs. acetaminophen 650mg, reported Daniel Qi, from McNeil Consumer Healthcare, Fort Washington, PA, at the American Pain Society’s 31st Annual Scientific Meeting.

A multiday, flexible dosing regimen of etoricoxib demonstrated greater improvements in worst recall pain, as well as reduced usage of study and rescue medication, compared with other standard therapies. Study investigators reported at the American Pain Society’s 31st Annual Scientific Meeting that the efficacy of etoricoxib was evaluated in a third-molar dental extraction study.

A trend towards less pain, functional interference and drowsiness, and improved patient satisfaction exists in patients who received continuous intravenous (IV) lidocaine treatment perioperatively, according to preliminary data from an ongoing, prospective, matched cohort, quality improvement study presented at the American Pain Society’s 31st Annual Scientific Meeting.

Naproxen significantly improved pain relief following arthroscopic surgery and reduced opioid utilization with no evidence of increased risk of adverse events, reported Evan Ekman, MD from Southern Orthopaedic Sports Medicine, Columbia, SC, at the American Pain Society’s 31st Annual Scientific Meeting.